α干扰素治疗原发性血小板增多症和其他骨髓增生性疾病伴血小板增多症

Xenophon Yataganas, John Meletis, Eleni Plata, Nora Viniou, Filippos Deligiannis, Christina Tsekoura, Ersi Voscaridou, Viki Boussiotis, John Rombos, Georges Vayopoulos, Christos Kittas, Phaedon Fessas
{"title":"α干扰素治疗原发性血小板增多症和其他骨髓增生性疾病伴血小板增多症","authors":"Xenophon Yataganas,&nbsp;John Meletis,&nbsp;Eleni Plata,&nbsp;Nora Viniou,&nbsp;Filippos Deligiannis,&nbsp;Christina Tsekoura,&nbsp;Ersi Voscaridou,&nbsp;Viki Boussiotis,&nbsp;John Rombos,&nbsp;Georges Vayopoulos,&nbsp;Christos Kittas,&nbsp;Phaedon Fessas","doi":"10.1016/0277-5379(91)90578-2","DOIUrl":null,"url":null,"abstract":"<div><p>The effect of recombinant interferon alfa-2b on platelet count, thrombocytosis-associated symptoms and marrow fibrosis was studied in 18 patients with myeloproliferative diseases and associated thrombocytosis (nine with essential thrombocythaemia, three with polycythaemia vera, three with myelofibrosis and three with chronic myelogenous leukaemia). A reduction of the platelet count below 600 × 10<sup>9</sup>/L was achieved in 94%, and below 400 × 10<sup>9</sup>/L in 77% of the patients within 8 to 330 days of treatment. The selective thrombocytosis-reducing effect of alpha interferon was maintained for long periods of time in most patients without serious side effects. Thrombocytosis-associated symptoms were relieved once the number of platelets was reduced to near normal levels. Marrow reticulin content was found to be reduced after treatment in two of the seven patients studied. Side effects of alpha interferon were flu-like symptoms, which usually subsided within 7 days of treatment.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S69-S71"},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90578-2","citationCount":"11","resultStr":"{\"title\":\"Alpha interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis\",\"authors\":\"Xenophon Yataganas,&nbsp;John Meletis,&nbsp;Eleni Plata,&nbsp;Nora Viniou,&nbsp;Filippos Deligiannis,&nbsp;Christina Tsekoura,&nbsp;Ersi Voscaridou,&nbsp;Viki Boussiotis,&nbsp;John Rombos,&nbsp;Georges Vayopoulos,&nbsp;Christos Kittas,&nbsp;Phaedon Fessas\",\"doi\":\"10.1016/0277-5379(91)90578-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The effect of recombinant interferon alfa-2b on platelet count, thrombocytosis-associated symptoms and marrow fibrosis was studied in 18 patients with myeloproliferative diseases and associated thrombocytosis (nine with essential thrombocythaemia, three with polycythaemia vera, three with myelofibrosis and three with chronic myelogenous leukaemia). A reduction of the platelet count below 600 × 10<sup>9</sup>/L was achieved in 94%, and below 400 × 10<sup>9</sup>/L in 77% of the patients within 8 to 330 days of treatment. The selective thrombocytosis-reducing effect of alpha interferon was maintained for long periods of time in most patients without serious side effects. Thrombocytosis-associated symptoms were relieved once the number of platelets was reduced to near normal levels. Marrow reticulin content was found to be reduced after treatment in two of the seven patients studied. Side effects of alpha interferon were flu-like symptoms, which usually subsided within 7 days of treatment.</p></div>\",\"PeriodicalId\":11925,\"journal\":{\"name\":\"European Journal of Cancer and Clinical Oncology\",\"volume\":\"27 \",\"pages\":\"Pages S69-S71\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1991-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0277-5379(91)90578-2\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer and Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0277537991905782\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0277537991905782","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

摘要

研究了重组干扰素α -2b对18例骨髓增生性疾病及相关血小板增多症患者(原发性血小板增多症9例,真性红细胞增多症3例,骨髓纤维化3例,慢性骨髓性白血病3例)血小板计数、血小板增多症相关症状及骨髓纤维化的影响。94%的患者在治疗后8 - 330天内血小板计数降至600 × 109/L以下,77%的患者降至400 × 109/L以下。在大多数患者中,α干扰素的选择性血小板减少作用维持了很长一段时间,没有严重的副作用。血小板数量减少到接近正常水平后,血小板增多相关症状得到缓解。在研究的七名患者中,有两名患者在治疗后发现骨髓网状蛋白含量降低。干扰素的副作用是流感样症状,通常在治疗7天内消退。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Alpha interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis

The effect of recombinant interferon alfa-2b on platelet count, thrombocytosis-associated symptoms and marrow fibrosis was studied in 18 patients with myeloproliferative diseases and associated thrombocytosis (nine with essential thrombocythaemia, three with polycythaemia vera, three with myelofibrosis and three with chronic myelogenous leukaemia). A reduction of the platelet count below 600 × 109/L was achieved in 94%, and below 400 × 109/L in 77% of the patients within 8 to 330 days of treatment. The selective thrombocytosis-reducing effect of alpha interferon was maintained for long periods of time in most patients without serious side effects. Thrombocytosis-associated symptoms were relieved once the number of platelets was reduced to near normal levels. Marrow reticulin content was found to be reduced after treatment in two of the seven patients studied. Side effects of alpha interferon were flu-like symptoms, which usually subsided within 7 days of treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Preclinical evaluation of polymer-bound doxorubicin Corrections News Introduction Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1